Inhibitor Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	1.84	1.97	2.02	0.65	0.32	0.87
Research & Development	1.75	1.68	1.38	0.01	0	0.19
Operating Expenses	3.6	3.66	3.4	0.66	0.33	1.06
Operating Income	-3.6	-3.66	-3.4	-0.66	-0.33	-1.06
Interest Expense	-	-	-	-0.02	-0.01	-
Interest & Investment Income	0.17	0.32	0.38	-	-	0
EBT Excluding Unusual Items	-3.43	-3.34	-3.03	-0.68	-0.34	-1.06
Legal Settlements	-	-	-	12.62	-	-
Other Unusual Items	-	-	-	0.22	0.04	-
Pretax Income	-3.43	-3.34	-3.03	12.16	-0.3	-1.06
Income Tax Expense	-	-	-	0.06	-	-
Net Income	-3.43	-3.34	-3.03	12.11	-0.3	-1.06
Preferred Dividends & Other Adjustments	-	-	-	0.19	0.2	0.2
Net Income to Common	-3.43	-3.34	-3.03	11.92	-0.5	-1.26
Shares Outstanding (Basic)	172	172	172	366	376	372
Shares Outstanding (Diluted)	172	172	172	366	376	372
Shares Change (YoY)	0.15%	0.18%	-53.04%	-2.67%	1.16%	0.40%
EPS (Basic)	-0.02	-0.02	-0.02	0.03	-0.00	-0.00
EPS (Diluted)	-0.02	-0.02	-0.02	0.03	-0.00	-0.00
EBIT	-3.6	-3.66	-3.4	-0.66	-0.33	-1.06
Effective Tax Rate	-	-	-	0.45%	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.